ClinicalTrials.gg
TerminatedNCT01732926BridalveilUpdated Nov 16, 2018Results posted

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

A Phase 3 interventional study of Idelalisib and Rituximab in Indolent Non-Hodgkin's Lymphomas, sponsored by Gilead Sciences. Terminated at 144 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
475
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing idelalisib in Lymphoma, Follicular — none open to participants now, none under way, none of them phase 3. idelalisib · Lymphoma, Follicular.

Enrollment
Largest of 12
475 · median 18
Started
2013
with 2 others
Phase 3
3 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
7 of 12
Gilead Sciences

Among the 12 studies testing idelalisib in Lymphoma, Follicular, this one has the largest enrollment, is one of 3 that started in 2013, is one of 3 in phase 3, and was the 4th registered.

Lymphoma, Follicular

1,892 studies on the registry are indexed under Lymphoma, Follicular; 290 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

None of the 12 studies testing idelalisib in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →

About idelalisib

idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing idelalisib in Lymphoma, Follicular as a file.
02

Study summary

The primary objective of this study is to evaluate the addition of idelalisib to bendamustine/rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).

An increased rate of deaths and serious adverse events (SAEs) among participants with front-line chronic lymphocytic leukemia (CLL) and early-line iNHL treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA).

03

Conditions studied

  • Indolent Non-Hodgkin's Lymphomas

Keywords

  • iNHL
  • indolent NHL
  • follicular lymphoma
  • CAL-101
  • rituximab
  • bendamustine
  • small lymphocytic lymphoma
  • lymphoplasmacytoid lymphoma
  • Waldenstrom macroglobulinemia
  • LPL
  • WM
  • Marginal zone lymphoma
  • MZL
  • SLL
  • FL
  • GS-1101
  • PI3K inhibitor
  • idelalisib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • confirmed diagnosis of B-cell iNHL, with histological subtype limited to the following

    1. Follicular lymphoma (FL) Grade 1, 2, or 3a
    2. Small lymphocytic lymphoma (SLL)
    3. Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM)
    4. Marginal zone lymphoma (MZL) (splenic, nodal, or extra-nodal)

Key Exclusion Criteria:

  • History of lymphoid other than those allowed per inclusion criteria.
  • Ongoing drug-induced liver injury, active , active , alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension.
  • Prior treatment with bendamustine that was not effective.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
475 participants (actual)

Study arms

  • Experimental
    Rituximab + Bendamustine + Idelalisib

    Participants will receive rituximab + bendamustine + idelalisib.

    Drug: Idelalisib · Drug: Rituximab · Drug: Bendamustine

  • Experimental
    Rituximab + Bendamustine + Placebo

    Participants will receive rituximab + bendamustine + placebo.

    Drug: Rituximab · Drug: Bendamustine · Drug: Placebo

Interventions

  • 150 mg tablet administered orally twice daily

    Also known as: Zydelig®, CAL-101, GS-1101

  • 375 mg/m\^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)

    Also known as: Rituxan®, MabThera®

  • 90 mg/m\^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)

    Also known as: Treanda®

  • DrugPlacebo

    Tablet administered orally twice daily

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS is defined as the interval from randomization to the earlier of the first documentation of definitive indolent non-Hodgkin lymphomas (iNHL) disease progression or death from any cause. Definitive iNHL disease progression is progression based on standard criteria. PFS was to be assessed by an independent review committee (IRC).

Secondary outcomes

  1. Complete Response Rate (CR)

    Complete response rate is defined as the proportion of participants who achieve a complete response. CR rate was to be assessed by an IRC.

  2. Overall Response Rate (ORR)

    Overall response rate is defined as the proportion of participants who achieve a complete response or partial response (or very good partial response (VGPR) or minor response (MR) for participants with Waldenstrom's). ORR was to be assessed by an IRC.

  3. Lymph Node Response Rate

    Lymph node response rate is defined as the proportion of participants who achieve ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Lymph node response rate was to be assessed by an IRC.

  4. Overall Survival (OS)

    Overall survival is defined as the interval from randomization to death from any cause.

07

Results

Posted May 11, 2017
Limitations and caveats
Due to the early termination of the study, efficacy data were not available for all participants, and therefore the prespecified analyses were not conducted.

Participant flow

Participants were enrolled at study sites in the North America, Europe, and Asia Pacific. The first participant was screened on 02 January 2013. The last study visit occurred on 17 May 2016.

Participant flow — Overall Study
MilestoneIdelalisib + Bendamustine + RituximabPlacebo + Bendamustine + Rituximab
Started320155
Completed5345
Not completed267110
Withdrew: Study terminated by sponsor16880
Withdrew: Withdrawal by subject468
Withdrew: Physician decision2411
Withdrew: Other reason214
Withdrew: Initiation of other anti-cancer therapy76
Withdrew: Blind broken by subject or study site11

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS is defined as the interval from randomization to the earlier of the first documentation of definitive indolent non-Hodgkin lymphomas (iNHL) disease progression or death from any cause. Definitive iNHL disease progression is progression based on standard criteria. PFS was to be assessed by an independent review committee (IRC).

No measurements were reported for this outcome.

SecondaryComplete Response Rate (CR)

Complete response rate is defined as the proportion of participants who achieve a complete response. CR rate was to be assessed by an IRC.

No measurements were reported for this outcome.

SecondaryOverall Response Rate (ORR)

Overall response rate is defined as the proportion of participants who achieve a complete response or partial response (or very good partial response (VGPR) or minor response (MR) for participants with Waldenstrom's). ORR was to be assessed by an IRC.

No measurements were reported for this outcome.

SecondaryLymph Node Response Rate

Lymph node response rate is defined as the proportion of participants who achieve ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Lymph node response rate was to be assessed by an IRC.

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

Overall survival is defined as the interval from randomization to death from any cause.

No measurements were reported for this outcome.

Adverse events

Collected over Up to 34 months plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Idelalisib + Bendamustine + Rituximab—229/317 (72.2%)315/317 (99.4%)
Placebo + Bendamustine + Rituximab—58/155 (37.4%)147/155 (94.8%)
Most frequent serious events
Showing 10 of 246
Most frequent serious events
EventIdelalisib + Bendamustine + RituximabPlacebo + Bendamustine + Rituximab
PyrexiaGeneral disorders67/3172/155
Febrile neutropeniaBlood and lymphatic system disorders45/3177/155
PneumoniaInfections and infestations24/3174/155
RashSkin and subcutaneous tissue disorders18/3170/155
PneumonitisRespiratory, thoracic and mediastinal disorders16/3170/155
DiarrhoeaGastrointestinal disorders14/3172/155
Alanine aminotransferase increasedInvestigations14/3170/155
Aspartate aminotransferase increasedInvestigations12/3170/155
ColitisGastrointestinal disorders9/3170/155
Pneumocystis jirovecii pneumoniaInfections and infestations9/3170/155
Most frequent other events
Showing 10 of 60
Most frequent other events
EventIdelalisib + Bendamustine + RituximabPlacebo + Bendamustine + Rituximab
NauseaGastrointestinal disorders159/31765/155
DiarrhoeaGastrointestinal disorders158/31733/155
PyrexiaGeneral disorders135/31722/155
NeutropeniaBlood and lymphatic system disorders122/31754/155
RashSkin and subcutaneous tissue disorders105/31716/155
FatigueGeneral disorders103/31751/155
VomitingGastrointestinal disorders100/31725/155
CoughRespiratory, thoracic and mediastinal disorders71/31737/155
ConstipationGastrointestinal disorders74/31731/155
Alanine aminotransferase increasedInvestigations65/3173/155

Baseline characteristics

The Intent to Treat (ITT) Analysis Set: all participants who were randomized regardless of whether they received any study treatment

Age, Continuous
Age, Continuous(years)Idelalisib + Bendamustine + RituximabPlacebo + Bendamustine + RituximabTotal
Mean62 ± 10.562 ± 11.162 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Idelalisib + Bendamustine + RituximabPlacebo + Bendamustine + RituximabTotal
Female13258190
Male18897285
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Idelalisib + Bendamustine + RituximabPlacebo + Bendamustine + RituximabTotal
Asian26834
Black or African American224
White247122369
Other426
Not Permitted412162
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Idelalisib + Bendamustine + RituximabPlacebo + Bendamustine + RituximabTotal
Hispanic or Latino16824
Not Hispanic or Latino262129391
Not Permitted421860
Region of Enrollment
Region of Enrollment(Participants)Idelalisib + Bendamustine + RituximabPlacebo + Bendamustine + RituximabTotal
Russian Federation161127
United States371249
United Kingdom332053
Spain211132
Canada471966
Czech Republic12719
Sweden325
Taiwan729
Poland251136
Korea, Republic of10212
Italy211435
Israel628
France361854
Australia442367
Germany213
08

Study locations

144 sites
  • Clearview Cancer Institute
    Huntsville, Alabama 35805, United States
  • Ironwood Cancer and Research Center
    Chandler, Arizona 85224, United States
  • Comprehensive Blood and Cancer Center (Bakersfield)
    Bakersfield, California 93309, United States
  • Saint Jude Heritage Healthcare (TORI)
    Fullerton, California 92835, United States
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • Cancer Care Associates
    Redondo Beach, California 90277, United States
  • San Luis Obispo Oncology and Hematology
    San Luis Obispo, California 93401, United States
  • Cancer Center of Santa Barbara
    Santa Barbara, California 93105, United States
  • Central Coast Medical Oncology Group
    Santa Maria, California 93454, United States
  • St Joseph Heritage Healthcare System
    Santa Rosa, California 95403, United States
  • Kaiser Permanente Vallejo Medical Center
    Vallejo, California 94589, United States
  • Sylvester Comprehensive Cancer Center/UMHC
    Deerfield Beach, Florida 33442, United States
  • Cancer Specialists of North Florida
    Jacksonville, Florida 32256, United States
  • Northwest Georgia Oncology Centers, PC
    Marietta, Georgia 30060, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Joliet Oncology Hematology Associates Ltd.
    Joliet, Illinois 60435, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
  • North Shore Hematology/Oncology Associates
    East Setauket, New York 11733, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Signal Point Clinical Research Center, LLC
    Middletown, Ohio 45042, United States
  • Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • Bon Secours Saint Francis Hospital
    Greenville, South Carolina 29607, United States
  • Texas Oncology, P.A.
    Bedford, Texas 76022, United States
  • Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Texas Oncology, P.A.
    Denton, Texas 76210, United States
  • Brooke Army Medical Center
    Fort Sam Houston, Texas 78234, United States
  • Texas Oncology, P.A.
    Harlingen, Texas 78550-8321, United States
  • Texas Oncology, P.A.
    Weslaco, Texas 78596-6608, United States
  • Swedish Medical Center
    Seattle, Washington 98104, United States
  • Northwest Medical Specialists
    Tacoma, Washington 98405, United States
  • Aurora BayCare Medical Center
    Green Bay, Wisconsin 54308, United States
  • Froedtert Hospital and Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Prince of Wales Hospital
    Randwick, New South Wales 2031, Australia
  • Haematology and Oncology Clinics of Australia Gold Coast
    South Brisbane, Queensland 4101, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Adelaide Cancer Centre
    Kurralta Park, South Australia 5037, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Saint Vincent's Hospital
    Fitzroy, Victoria 3065, Australia
  • Western Hospital
    Footscray, Victoria 3011, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • Tom Baker Cancer Center
    Calgary, Alberta T2N 2T9, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Fraser Clinical Trials, Inc.
    New Westminster, British Columbia V3L 3W4, Canada
  • BC Cancer Agency - Vancouver Centre
    Vancouver, British Columbia V5Z 4E6, Canada
  • Queen Elizabeth II Health Sciences Centre, Centre for Clinical Research
    Halifax, Nova Scotia B3H 1V7, Canada
  • Royal Victoria Regional Health Centre
    Barrie, Ontario L4M 6M2, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • Hôpital Charles Lemoyne
    Greenfield Park, Quebec J4V 2H1, Canada
  • McGill University Health Centre
    Montréal, Quebec H4A 3JI, Canada
  • Centre Hospitalier Universitaire de Sherbrooke
    Sherbrooke, Quebec J1H 5N4, Canada
  • Centre Hospitalier Affilie Universitaire de Quebec
    Quebec, G1J 1Z4, Canada
  • CancerCare Manitoba
    Winnipeg, R3E 0V9, Canada
  • Fakultní Nemocnice Ostrava
    Ostrava - Poruba, Severomoravsky KRAJ 708 52, Czechia
  • Fakultní nemocnice Brno
    Brno, 625 00, Czechia
  • Fakultní nemocnice Hradec Králové
    Hradec Králové, 500 05, Czechia
  • CHR Metz
    Metz Cedex 03, Alsace 57085, France
  • Centre Hospitalier Universitaire de Strasbourg - Hôpital Hautepierre
    Strasbourg Cedex, Alsace 67098, France
  • Institut Bergonié
    Bordeaux Cedex, Aquitaine 33076, France
  • Centre Henri-Becquerel
    Rouen Cedex 1, Haute-normandie 76038, France
  • Hôpital Necker-Enfants Malades
    Paris, Ile-de-france 75015, France
  • Centre Jean Bernard
    Le Mans, PAYS DE LA Loire 72000, France
  • Centre Hospitalier Lyon Sud
    Pierre Bénite Cedex, Rhone-alpes 69495, France
  • Centre Hospitalier Universitaire Brest
    Brest Cedex, 29609, France
  • Centre Hospitalier de Dunkerque
    Dunkerque, 59385, France
  • Centre Hospitalier Départmental La Roche sur Yon
    La Roche sur Yon, 85925, France
  • Centre Léon Bérard
    Lyon Cedex 08, 69373, France
  • Institut Paoli Calmettes
    Marseille, 13273, France
  • Hôpital Hôtel-Dieu
    Nantes cedex 1, 44093, France
  • Centre Hospitalier Universitaire de Poitiers
    Poitiers Cedex, 86021, France
  • Centre Hospitalier Régional et Universitaire - Hôpital Bretonneau
    Tours, 37044, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH
    Villingen-Schwenningen, Baden-wuerttemberg 78054, Germany
  • Gemeinschaftspraxis Dres. Söling Und Siehl
    Kassel, Hessen 34117, Germany
  • Vivantes Klinikum am Urban
    Berlin, 10967, Germany
  • Charite - Campus Virchow
    Berlin, 13353, Germany
  • Klinikum der Ludwig-Maximilians-Universität München
    München, 81377, Germany
  • Barzilai Medical Center
    Ashkelon, 78278, Israel
  • Soroka University Medical Center
    Beer Sheva, 84101, Israel
  • Rambam Health Corp.
    Haifa, 31096, Israel
  • Hadassah Medical Organization, Ein Kerem
    Jerusalem, 91120, Israel
  • Centro di Riferimento Oncologico di Aviano
    Aviano, 33081, Italy
  • Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi
    Bologna, 40138, Italy
  • Spedali Civili Di Brescia Azienda Ospedaliera
    Brescia, 25123, Italy
  • IRCCS Azienda Ospedaliera Universitaria San Martino
    Genova, 16132, Italy
  • Ospedale San Raffaele-IRCCS
    Milano, 20132, Italy
  • Azienda Ospedaliera Ospedale Niguarda Ca' Granda
    Milano, 20162, Italy
  • Azienda Ospedaliero Universitaria (AOU) "Maggiore della Carita" di Novara
    Novara, 28100, Italy
  • Azienda Ospedaliera Ospedali Riuniti Marche Nord
    Pesaro, 61122, Italy
  • Azienda Unità Sanitaria Locale di Piacenza-Ospedale Guglielmo da Saliceto
    Piacenza, 29100, Italy
  • Azienda Ospedaliera Universitaria Senese - Policlinico S. Maria alle Scotte
    Siena, 53100, Italy
  • Azienda Ospedaliera Città della Salute e della Scienza di Torino
    Torino, 10126, Italy
  • Dong-A University Medical Center
    Busan, 602-715, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 110-744, Korea, Republic of
  • Samsung Medical Center
    Seoul, 135-710, Korea, Republic of
  • Asan Medical Center
    Seoul, 138-736, Korea, Republic of
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-952, Poland
  • Malopolskie Centrum Medyczne S.C.
    Kraków, 30-510, Poland
  • Szpital Kliniczny nr 1, Katedra i Klinika Hematoonkologii i Transplantacji Szpiku
    Lublin, 20-081, Poland

Showing the first 100 of 144 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2013 to primary completion in May 2016, 40 months.

Results were first posted in May 2017, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2012
First posted
Nov 26, 2012
StartActual
Jan 2, 2013
Primary completionActual
May 17, 2016
CompletionActual
May 17, 2016
Results first posted
May 11, 2017
Last update
Nov 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01732926
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 26, 2012
Start date
Jan 2, 2013
Primary completion
May 17, 2016
Completion
May 17, 2016
Results posted
May 11, 2017
Last update
Nov 16, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idelalisib

Start the discussion